Case report demonstrates accurate diagnosis of a PROS1 variant in a patient with thrombosis, suggesting improved clinical management strategies.
Hereditary protein S deficiency, a risk factor for venous thromboembolism, presents diagnostic challenges due to the PROS1 gene's homologous pseudogene, PROSP. The pseudogene's homology risks co-amplification and misinterpretation of sequencing data, leading to false results and compromising clinical management. We report a case of a 28-year-old male who presented dural venous sinus thrombosis and low free protein S. After a novel PROS1 variant was identified via next-generation sequencing, a "pseudogene-aware" Sanger sequencing assay was developed to validate the finding. This assay utilized primers designed in silico method and high-temperature PCR to exploit nucleotide mismatches between PROS1 and PROSP, ensuring targeted amplification. The assay successfully validated a novel heterozygous missense variant, PROS1:c.1484T>C. This variant co-segregated with low protein S levels in the family and was classified as likely pathogenic. This pseudogene-aware strategy enabled the accurate identification of a novel variant causing severe thrombophilia, highlighting the importance of such assays for reliable molecular diagnosis and patient management.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: